Skip to main content

Atopic Dermatitis (Eczema) clinical trials at UCSF

6 in progress, 3 open to eligible people

Showing trials for
  • Allergic Disease Onset Prevention Study

    open to all eligible people

    This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1 hypersensitivity). Subjects will be enrolled in a three-part sequential approach. Participants in the safety-run portion of the study (Part A1: 1 year to <6 years of age and A2: 1 month to <12 months of age) will receive 28 days of treatment with STMC-103H or placebo, followed by 28 days of follow-up. A Data and Safety Monitoring Committee (DSMC) will review safety data after all patients in each part complete 28 days of therapy prior to enrolling the next part. After A2, Part B will enroll 224 patients for 336 days of treatment with STMC-103H or placebo, followed by 336 days of follow-up. Stool, blood, and optional samples will be collected in Parts A2 and part B. Primary safety endpoints are frequency, type and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), as well as findings on physical exams, vitals, and safety laboratories. The primary efficacy endpoint is incidence of physician-diagnosed atopic dermatitis at day 336.

    San Francisco, California and other locations

  • Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

    open to eligible people ages 18 years and up

    This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.

    San Francisco, California

  • Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use

    open to eligible people ages 13 years and up

    Design and beta-test a research-oriented mobile health app to assess disease activity, quality of life, treatment patterns, adverse medication effects, and lifestyle factors in patients with atopic dermatitis.

    San Francisco, California

  • Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

    Sorry, in progress, not accepting new patients

    The main purpose of the study is to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

    San Francisco, California and other locations

  • Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

    Sorry, in progress, not accepting new patients

    This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed. Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.

    Fresno, California and other locations

  • The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

    Sorry, in progress, not accepting new patients

    This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.

    San Francisco, California

Our lead scientists for Atopic Dermatitis (Eczema) research studies include .

Last updated: